The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction

Netherlands Heart Journal

Volumn 24, Issue 4, 2016, Pages 259-267

  Franssen, C ^a   Gonzalez Miqueo A ^b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Biomarkers; Extracellular matrix; HFpEF; Myocardial remodeling; Myocardial stiffness; Titin

Indexed keywords

CONNECTIN;

CARDIOVASCULAR MAGNETIC RESONANCE; EXTRACELLULAR MATRIX; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE FIBROSIS; HUMAN; INFLAMMATION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MOLECULAR INTERACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 84963655336     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-016-0812-z     Document Type: Review

References (62)

1. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-847.
2. Redfield MM. Understanding ‘Diastolic’ Heart Failure. N Engl J Med. 2004;350:1930-1.
3. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-71.
4. Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175:996-1004.
5. Collier P, Watson CJ, Voon V, et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail. 2011;13:1087-95.
6. Kalogeropoulos A, Georgiopoulou V, Psaty BM, et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol. 2010;55:2129-37.
7. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507-15.
8. Aurigemma GP, Zile MR, Gaasch WH. Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation. 2006;113:296-304.
9. Borlaug BA, Kass DA. Invasive hemodynamic assessment in heart failure. Cardiol Clin. 2011;29:269-80.
10. Lester SJ, Tajik AJ, Nishimura RA, Oh JK, Khandheria BK, Seward JB. Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. J Am Coll Cardiol. 2008;51:679-89.
11. Sys U, Brutsaert L. Relaxation and Diastole of the Heart. Physiol Rev. 1989;69:1228-315.
12. Borbély A, van der Velden J, Papp Z, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111:774-81.
13. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2014;131:550-9.
14. Westermann D, Lindner D, Kasner M, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2011;4:44-52.
15. Díez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens. 2007;9:546-50.
16. Kasner M, Westermann D, Lopez B, et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol. 2011;57:977-85.
17. Van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117:43-51.
18. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest. 1999;104:103-13.
19. Zieman SJ, Melenovsky V, Clattenburg L, et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens. 2007;25:577-83.
20. Zhang M, Kho AL, Anilkumar N, et al. Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. Circulation. 2006;113:1235-43.
21. Mewton N, Liu CY, Croisille P, Bluemke D, Lima JAC. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57:891-903.
22. Su M-YM, Lin L-Y, Tseng Y-HE, et al. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging. 2014;7:991-7.
23. López B, González A, Ravassa S, et al. Circulating biomarkers of myocardial fibrosis. J Am Coll Cardiol. 2015;65:2449-56.
24. Mascherbauer J, Marzluf BA, Tufaro C, et al. Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging. 2013;6:1056-65.
25. De Boer RA, Daniels LB, Maisel AS, Januzzi JL. State of the Art: newer biomarkers in heart failure. Eur J Heart Fail. 2015;17:559-69.
26. Zile MR, Baicu CF. Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res. 2013;6:501-15.
27. AbouEzzeddine OF, Haines P, Stevens S, et al. Galectin-3 in heart failure with preserved ejection fraction. JACC Heart Fail. 2015;3:245-52.
28. Zile MR, Baicu CF, Ikonomidis J, et al. Myocardial Stiffness in Patients with Heart Failure and a Preserved Ejection Fraction: contributions of Collagen and Titin. Circulation. 2015;131:1247-59.
29. Van Heerebeek L, Borbély A, Niessen HWM, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113:1966-73.
30. Chung CS, Granzier HL. Contribution of titin and extracellular matrix to passive pressure and measurement of sarcomere length in the mouse left ventricle. J Mol Cell Cardiol. 2011;50:731-9.
31. Linke WA, Hamdani N. Gigantic business: titin properties and function through thick and thin. Circ Res. 2014;114:1052-68.
32. Hamdani N, Franssen C, Lourenço A, et al. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail. 2013;6:1239-49.
33. López B, González A, Hermida N, Valencia F, de Teresa E, Díez J. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol. 2010;299:H1-H9.
34. Collier P, Watson CJ, van Es MH, et al. Getting to the heart of cardiac remodeling; how collagen subtypes may contribute to phenotype. J Mol Cell Cardiol. 2012;52:148-53.
35. López B, Querejeta R, González A, Larman M, Díez J. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. Hypertension. 2012;60:677-83.
36. Granzier H, Labeit S. Structure-function relations of the giant elastic protein titin in striated and smooth muscle cells. Muscle Nerve. 2007;36:740-55.
37. Sequeira V, Nijenkamp LLAM, Regan JA, Van Der Velden J. The physiological role of cardiac cytoskeleton and its alterations in heart failure. Biochim Biophys Acta. 2014;1838:700-22.
38. Lewinter MM, Granzier HL. Cardiac titin and heart disease. J Cardiovasc Pharmacol. 2013;63:1-18.
39. Krüger M, Linke WA. Protein kinase-A phosphorylates titin in human heart muscle and reduces myofibrillar passive tension. J Muscle Res Cell Motil. 2006;27:435-44.
40. Hidalgo C, Hudson B, Bogomolovas J, et al. PKC phosphorylation of titin’s PEVK element: a novel and conserved pathway for modulating myocardial stiffness. Circ Res. 2009;105:6318.
41. Krüger M, Kötter S, Grützner A, et al. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res. 2009;104:87-94.
42. Raskin A, Lange S, Banares K, et al. A novel mechanism involving four-and-a-half LIM domain protein-1 and extracellular signalregulated kinase-2 regulates titin phosphorylation and mechanics. J Biol Chem. 2012;287:29273-84.
43. Hidalgo CG, Chung CS, Saripalli C, et al. The multifunctional Ca(2+)/calmodulin-dependent protein kinase II delta (CaMKIIδ) phosphorylates cardiac titin’s spring elements. J Mol Cell Cardiol. 2013;54:90-7.
44. Hamdani N, Krysiak J, Kreusser MM, et al. Crucial role for Ca2(+)/calmodulin-dependent protein kinase-II in regulating diastolic stress of normal and failing hearts via titin phosphorylation. Circ Res. 2013;112:664-74.
45. Borbély A, Falcao-Pires I, van Heerebeek L, et al. Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res. 2009;104:780-6.
46. Bishu K, Hamdani N, Mohammed SF, et al. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation. 2011;124:2882-91.
47. Kötter S, Gout L, Von Frieling-Salewsky M, et al. Differential changes in titin domain phosphorylation increase myofilament stiffness in failing human hearts. Cardiovasc Res. 2013;99:648-56.
48. Van Heerebeek L, Hamdani N, Falcão-Pires I, et al. Low myocardial protein kinase g activity in heart failure with preserved ejection fraction. Circulation. 2012;126:830-9.
49. Denninger JW, Marletta MA. Guanylate cyclase and the ⋅NO/ cGMP signaling pathway. Biochim. 1999;1411:334-50.
50. Münzel T, Genth-Zotz S, Hink U. Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure? Hypertension. 2007;49:974-6.
51. Hamdani N, Hervent A-S, Vandekerckhove L, et al. Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. Cardiovasc Res. 2014;104:423-31.
52. Grützner A, Garcia-Manyes S, Kötter S, Badilla CL, Fernandez JM, Linke WA. Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence. Biophys J. 2009;97:825-34.
53. Alegre-Cebollada J, Kosuri P, Giganti D, et al. S-glutathionylation of cryptic cysteines enhances titin elasticity by blocking protein folding. Cell. 2014;156:1235-46.
54. Zhang W, Lavine KJ, Epelman S, et al. Necrotic myocardial cells release damage-associated molecular patterns that provoke fibroblast activation in vitro and trigger myocardial inflammation and fibrosis in vivo. J Am Heart Assoc. 2015;4:e001993.
55. Banerjee I, Yekkala K, Borg TK, Baudino TA. Dynamic interactions between myocytes, fibroblasts, and extracellular matrix. Ann N Y Acad Sci. 2006;1080:76-84.
56. Zhang M, Shah AM. ROS signalling between endothelial cells and cardiac cells. Cardiovasc Res. 2014;102:249-57.
57. Greene SJ, Gheorghiade M, Borlaug BA, et al. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc. 2013;2:e000536.
58. Redfield MM, Borlaug BA, Lewis GD, et al. PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. Circ Heart Fail. 2012;5:653-9.
59. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-9. doi:10.1093/eurheartj/ehq426.
60. Heymans S et al. Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. Eur J Heart Fail. 2015;17:764-71. doi:10.1002/ejhf.312.
61. Kasner M et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol. 2011;57:977−85. doi:10.1016/j.jacc.2010.10.024.
62. Hamdani N, Linke WA. Gigantic business: titin properties and function through thick and thin. Circ Res. 2014;114:1052-68. doi:10.1161/CIRCRESAHA.114.301286.